![]() ![]() Theirs is a 2-sided (consumer and merchant) ecosystem. Paytm offers ‘Payment Services’, ‘Commerce and Cloud Services’, and ‘Financial Services’ to 33.3 crore consumers and over 2.18 crore merchants registered with them, as of June 30, 2021. The company today is India’s leading digital ecosystem for consumers and merchants. One97 Communications Limited was incorporated on December 22, 2000. Should you invest in One97 Communications (PayTM) IPO and will it make money for you? We help you find answers. This is also the costliest mainboard IPO in terms of share price by virtue of the Rs 2,080-2,150 per share tag, that surpasses the record held by Dix Technologies (â‚✑766 per equity share). The IPO is the biggest-ever for the Indian capital markets, and eclipses Coal India’s then mammoth offer. ![]() Founder promoter Vijay Shekar Sharma, along with other marquee investors such as Antfin (Netherlands), Singapore E-Commerce and BH International Holdings are selling partial stakes in the IPO. The offer worth â‚✑8,300 crore, comprises a fresh issue of â‚✘,300 crore and the rest being offer for sale. This will show you the status of the application.The much-awaited IPO of One97 Communications, the holding company that owns and operates the PayTM super app and other allied businesses, is opening November 8, 2021. Then you just click the ‘I am not a robot’ to verify yourself and click ‘Search’. There you need to select the ‘Equity’ option.ģ) Select ‘Windlas Biotech Limited’ from the drop-down menu that is besides the issue name.Ĥ) Input your application number and the Permanent Account Number (PAN). Via the URL ().Ģ) It will take you to a page called ‘Status of Issue Application’. How to Check Windlas Biotech IPO Allotment Status via BSEġ) Go to the official BSE website. Investors can check share in two ways on Wednesday - 1) Via BSE, 2) Via the IPO registrar’s website. ![]() Currently, the focus of the company is to launch complex generic products in the chronic therapeutic category related to lifestyle-related disorders. It further sells its own branded products in the trade generics and over-the-counter (OTC) markets. ![]() Incorporated in 2001, Windlas Biotech offers a range of contract development and manufacturing organization (CDMO) services from product discovery to product development, licensing, and commercial manufacturing of generic products including complex generics. The proceeds will be used for purchasing the equipment required for capacity expansion of its existing facility at the Dehradun plant – IV, addition of injectables dosage capability at existing facility at Dehradun plant – II, working capital requirements, and repayment of borrowings. Windlas Biotech aims to mobilise Rs 401.53 crore through its public offer, comprising a fresh issue of Rs 165 crore and an offer for sale of Rs 236.53 crore by Vimla Windlass, and Tano India Private Equity Fund II. The portion set aside for non-institutional investors was booked 15.73 times, while the retail portion saw a 24.27 times subscription. The portion reserved for the institutional buyers. Windlas Biotech IPO received bids for 13.78 crore equity shares against the IPO size of 61.36 lakh equity shares. The IPO of pharmaceutical formulations contract development and manufacturing organisation was subscribed 22.47 times. Windlas Biotech initial public offering (IPO) is expected to finalise the share allotment status on Wednesday. ![]()
0 Comments
Leave a Reply. |